B
iliary atresia (BA) is a devastating condition uniquely restricted to the neonatal period in which fibroinflammatory obstruction of the extrahepatic biliary tree leads to progressive jaundice and rapid fibrosis. Despite attempts to restore bile drainage by Kasai portoenterostomy (KPE) surgery at the time of diagnosis, biliary fibrosis progresses in up to 75% of affected children; thus, BA is the most common indication for pediatric liver transplantation (LTx) worldwide. More than 1,800 children underwent a first LTx for BA in the United States between 2002 and 2012. Of those transplanted before 2 years of age the outcome was inferior compared with those transplanted at a later age, indicating the need to develop adjuvant therapies to prolong transplant-free survival. (1) The etiology of BA is multifactorial. Potential causes include dysregulation of biliary development and exposure to environmental triggers such as toxins or viruses, as recently reviewed. (2) Immune-mediated injury to the bile duct epithelial cells (BECs) appears to be the common final pathway leading to the BA phenotype regardless of the initial trigger. Several studies using human samples and the well-established model of experimental BA have furthered our understanding of the immunopathogenesis of BA. Inoculation of neonatal BALB/c mice with rhesus rotavirus (RRV) leads to inflammatory extrahepatic bile duct obstruction by 7 days of life and death in the majority of infected animals after 14 days. In this model, initiation of injury has been linked to (1) early innate responses involving plasmacytoid dendritic cell (pDC)-dependent natural killer (NK) cell activation with NK group 2D (NKG2D) and interferon-gamma (IFN-c) regulating BEC injury (3, 4) and (2) adaptive regulatory T cells modulating susceptibility to duct obstruction and ability of myeloid (m)DCs to activate cytotoxic cluster of differentiation 8-positive (CD8 1 ) T lymphocytes. (5, 6) In infants with BA, hepatic gene expression for T helper 1 (Th1) and Th2 cytokines correlated with clinical phenotypes of BA. (7, 8) Oligoclonal expansion of hepatic CD4
1 and CD8 1 T lymphocytes, indicating antigen-specific immune responses, (9) and altered suppressor function of regulatory T cells (10) have been reported. Natural history studies of patients with BA document progressive intrahepatic bile duct loss in the majority of the patients by 400 days of life, despite bile duct proliferation noticed at the time of diagnosis. (11) While the mechanism of injury to BECs in BA causing progressive loss of intrahepatic bile ducts is unknown, studies in primary biliary cirrhosis linked CD4
1 lymphocytes with immune-mediated injury against intrahepatic BECs. For instance, increased number of intrahepatic CD4
1 Th17 cells and elevated plasma levels of Th17-associated cytokines correlated with serum levels of gamma glutamyl transpeptidase, a biochemical markers of small duct injury. (12) The role of CD4
1 lymphocytes in the pathogenesis of BA is largely undefined. We hypothesized that polarized T helper lymphocyte responses orchestrate progression of biliary injury in the later stage of BA pathogenesis.
Materials and Methods

HUMAN SAMPLES
Fresh liver samples were obtained by wedge biopsy from infants with BA at the time of diagnosis by intraoperative cholangiogram (n 5 6, median age 2 months) or at the time of LTx (n 5 7, median age 9 months) at Cincinnati Children's Hospital Medical Center (CCHMC). Archived paraffin-embedded liver sections from deidentified patients with BA were obtained by collaboration with pathologists (R.S. and P.R.) at CCHMC/BioBank and at Children's Hospital of Philadelphia. Archived liver sections from background, non-neoplastic liver from infants who underwent resection of benign neoplasms served as controls (n 5 4, age 12 months) as well as a patient with Alagille syndrome (n 5 1, 44 months). Blood was collected at CCHMC from infants with BA at diagnosis/KPE (n 5 3, median age 2 months) and at the time of LTx (n 5 4, median age 11 months) and from infants without clinical diagnosis of liver disease and normal serum liver biochemistries (n 5 4, median age 9 months). Human study protocols conformed to the ethical guidelines of the 1975 Declaration of Helsinki and were approved by the institutional review board.
MICE
Wild type BALB/c and CD11c/green fluorescent protein (GFP)/diphtheria toxin (DT) receptor (DTR) were purchased from Charles River (Wilmington, MA) and The Jackson Laboratories (Bar Harbor, ME), respectively. Interleukin 17A (IL-17A)-GFP and IL-17 receptor A (IL-17RA) knockout mice were obtained from Biocytogen LLC (Worcester, MA) and from Amgen Pharmaceuticals (Thousand Oaks, CA), respectively, and backcrossed into the BALB/c strain at the CCHMC animal facility for 10 generations. The transgenic mice have been described. (13) (14) (15) Mice were kept in conventional conditions (258C, 12 hours of daylight, ad libitum autoclaved chow). IL-17RA knockout mice and their controls were maintained on a 5053 LabTest diet with 275 ppm sulfamethoxazole and 1,365 ppm trimethoprim (LabDiet, Richmond, IN). The Animal Care and Use Committee at CCHMC approved all experiments involving laboratory animals.
MURINE MODEL OF BA
For experimental BA, pups were injected intraperitoneally with 1.5 3 10 6 focus forming units of RRV in 20 lL of 0.9% normal saline (NS) within 24 hours of birth, as performed by our group before. (5, 6) Details for DC depletion in CD11c/GFP/DTR mice and chemokine (C-C motif) receptor 2 (CCR2) blockade are available in Supporting Information. Mononuclear cells (MNCs) and intrahepatic cholangiocytes were isolated from neonatal mice and used in flow-cytometric studies and coculture experiments according to protocols reported by us before. (5, 6, 16) Quantitative hepatic gene expression studies on complementary DNA samples were performed using TaqMan Mouse Immune Array and run on a 7900HT Fast Real-Time polymerase chain reaction system (Applied Biosystems) according to the manufacturer's protocol. Details are provided in Supporting Information.
IMMUNOHISTOCHEMISTRY, IMMUNOFLUORESCENCE, AND AUTOMATED IMAGE ANALYSIS
STATISTICS
Statistical analyses were performed with GraphPad Prism software. Statistical significance was determined by paired or unpaired t test (as indicated in figure legends), with significance set at P < 0.05. Statistical differences between survival curves were calculated by log-rank (Mantel-Cox) test. Linear regression analysis 
2 ), and CD8 (CD8 2 MNCs. Bar graphs are means 6 standard error of the mean. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001, determined by unpaired t test. Each dot represents results from an individually treated animal.
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was applied to relative messenger RNA (mRNA) concentrations from cholangiocytes exposed to various concentrations of recombinant IL-17A (rIL-17A).
Results
Th17 LYMPHOCYTES POPULATE THE LIVER DURING THE LATE PHASE OF EXPERIMENTAL BA
To delineate the predominant immune responses during the phases of experimental BA, we analyzed the composition of putative effector lymphocytes at 4, 8, and 12 days post-NS or post-RRV injection (d4/8/ 12pNS or pRRV) in the target tissue of injury (liver) and in a secondary lymphoid organ (spleen). The proportions of innate NK cells, NK T (NKT) cells, and T-cell receptor (TCR) cd lymphocytes increased in the liver during the early phase of BA and diminished thereafter to frequencies similar to or lower than those found in control pups (Fig. 1A) . In contrast, the frequencies of adaptive CD4
1 and CD8 1 T cells increased significantly at later time points (d8/ 12pRRV). Their expansion was specific for the liver, whereas their frequencies diminished in the spleen (Supporting Fig. S1 ). A majority of intrahepatic CD4 1 and CD8 1 T cells expressed the activation marker CD69, while CD8 1 lymphocytes expressed also high levels of NKG2D, previously implicated in bile duct epithelial injury (Fig. 1B) . Whereas the plasma concentrations of IFN-c and IL-13, the signature Th1 and Th2 cytokines, respectively, were comparable between RRV-treated and NS-treated mice at the later time points, IL-17A concentration was significantly higher on day 12 in RRV-infected mice (Fig. 1C) . When MNCs from both groups of mice were restimulated with anti-CD3 in vitro, significant production of IL-17A occurred in cultures from hepatic MNCs of RRV-infected mice and not from noninfected mice or from splenic MNCs (Fig. 1D) . In order to identify unequivocally the cellular source for IL-17A production in the liver, we challenged neonatal IL-17A-GFP reporter mice with RRV at birth. GFP 1 (IL-17A ) increased more than 2-fold in liver and spleen at d12pRRV ( Fig. 2A,B) . Most of the hepatic DCs belonged to the mDC subset (CD11b 
CD4
1 lymphocytes and hepatic Il-17a mRNA expression (Fig.  3C ). Restimulated MNCs from DT-treated pups produced lower levels of IL-17A than MNCs from control pups in vitro (Fig. 3C) . Importantly, DT-induced reduction of CD11c 1 DCs significantly lowered serum total bilirubin levels, a biomarker for cholestasis and bile duct injury (Fig. 3D ). Histomorphological analysis of liver sections subjected to cytokeratin 19 (CK19) IHC, identifying BECs, revealed preserved interlobular bile ducts with normal lumen in >50% of portal triads in DT-treated animals, while livers from vehicletreated mice predominantly showed dystrophic bile duct profiles indicating bile duct paucity (Fig. 3E) .
IL-17A SIGNALING CONTROLS RECRUITMENT OF INFLAMMATORY MACROPHAGES TO THE SITE OF EPITHELIAL INJURY IN BA
IL-17RA forms a heterodimer with IL-17RC, which serves as the receptor for IL-17A and IL-17F. IL-17A signaling is disrupted in IL-17RA 2/2 mice. Following postnatal RRV infection, genes encoding Cd40, endothelin 1, and Ifn-c were up-regulated and 
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2 MNCs from neonatal mice at d12pNS/RRV. (B) Left panels: frequencies of DCs in MNCs, and of CD11b 1 cells in 7AADthose encoding Cd45, Ccr2, Il-1b, and Icos were down-regulated in IL-17RA 2/2 compared with IL-17RA 1/1 mice (Fig. 4A) . Candidate quantitative polymerase chain reaction studies confirmed significant down-regulation of hepatic mRNA expression for Ccr2 and its ligand Ccl2. Examining the role of the CCL2/CCR2 axis in RRV-infected wild-type mice, we found that plasma CCL2 levels were elevated at d12pRRV, coinciding with the emergence of inflammatory macrophages (iMU; Ly6C
2 ) in the liver (Fig. 4B) . The immune cells expressing CCR2 were mainly Ly6C hi iMU, whereas T and B lymphocytes or monocytes were less prevalent within the hepatic CCR2 1 leukocyte compartment during the late phase of BA. Importantly, treatment with the specific small molecule CCR2 antagonist RS504393 on d8/9pRRV decreased the number of CCR2
1 immune cells and of iMU in the liver on d10pRRV (Fig. 4C) . When probing further whether down-regulation of Ccl2 expression in mice lacking IL-17A signaling had consequences for leukocyte recruitment, we found by flow-cytometric and IHC analyses that the frequency of Ly6C 1 iMU in the liver and accumulation of F4/80 1 MU around interlobular bile ducts were diminished in IL-17RA ( Fig. 4D,E) . Importantly, these changes were associated with improved survival of RRV-infected IL-17RA 2/2 mice (Fig. 4F ). To determine whether IL-17A exerts epithelial injury, we examined its receptor expression on primary neonatal cholangiocytes and the functional responses of these cells to cytokine stimulation in vitro. IL-17RA coexpressed with the cholangiocyte marker CK19, as shown by direct immunofluorescence (IF) (Fig. 5A) . No difference in survival of primary cholangiocytes cultured for 48 hours with rIL-17A was observed in a 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium colorimetric assay (Supporting Fig. S3 ). While IL-17A was not directly cytopathic to BECs, we found that incubation with rIL-17A for 24 hours induced mRNA expression of Ccl2, Cxcl1, Cxcl5, and Il-6 in vitro (Fig. 5B) .
IL-17A INDUCES EXPRESSION OF Th17 POLARIZING CYTOKINES IN HEPATIC LEUKOCYTES
We hypothesized that IL-17A may not only promote recruitment of inflammatory cells to the bile duct epithelium but also up-regulate expression of proinflammatory cytokines in leukocytes. Thus, we isolated CD11b 1 myeloid cells from livers and spleens of RRV-infected pups, which contained neutrophils, monocytes, and MU (Supporting Fig. S4A ). The cells were restimulated in vitro with rIL-17A for 6 hours, which resulted in increased expression of Il-6 and Il-23p19 (Supporting Fig. S4B ), especially in hepatic CD11b 1 cells containing a higher proportion of iMU.
CHOLANGIOCYTES AND MACROPHAGES EXPRESS IL-17RA IN PATIENTS WITH BA
In order to investigate whether Th17 lymphocytes are linked to BEC injury in humans with BA, we performed dual IF on liver sections for IL-17RA and AE1/AE3, a marker for cholangiocytes. The two proteins coexpressed in a neonate without cholestasis and in an infant with BA at the time of diagnosis (Fig.  5C) . Furthermore, hepatic iMU, identified by the surface marker CD68, expressed IL-17RA in patients with BA at diagnosis and at the time of LTx (Supporting Fig. S4C ).
ACTIVATED CD4 1 LYMPHOCYTES AND mDCs ARE PRESENT IN THE LIVERS OF INFANTS WITH BA
Multiparameter flow cytometry on fresh liver tissue samples from patients with BA at diagnosis identified NK, CD4
1
, and CD8 1 cells as prominent lymphocyte populations, with a lower frequency of NKT cells (Fig.  6A,B) . Activated CD4 1 and CD8 1 T lymphocytes (expressing low levels of CD127) were more frequent in liver than in blood of BA patients (Fig. 6C) . Analysis of DC populations demonstrated predominance of CD11c 1 mDCs over CD123 1 pDCs (Fig. 6D,E ). Similar to experimental BA, hepatic CD11c 1 DCs   FIG. 4 . IL-17A controls recruitment of inflammatory macrophages to the liver through the CCL2/CCR2 pathway. (A) Loss of IL-17A signaling diminishes hepatic Ccl2/Ccr2 expression. Neonatal IL-17RA 1/1 and IL-17RA 2/2 mice were challenged with RRV postnatally, livers were harvested on d10pRRV, and hepatic expression of 88 genes encoding cytokines and chemokines was quantitated using TaqMan low-density arrays. Heatmap, representing the hierarchical clustering of Hprt-normalized mRNA expression, depicts the genes with P < 0.2 for FC difference between the groups. FC and *P < 0.05 was indicated. Expression of mRNA encoding Ccr2 and Ccl2 was validated by SYBR green quantitative polymerase chain reaction (n pups/group >3). (B) The CCL2/CCR2 axis controls recruitment of inflammatory MU to the liver in experimental BA. Plasma CCL2 concentrations from mice at d12pNS/RRV were measured by enzyme-linked immunosorbent assay. Kinetics of emergence of iMU (Ly6C
2 ) in the liver was enumerated by flow cytometry. Representative plot for the expression of Ly6C and CCR2 in hepatic MU (CD11b 1/1 and IL-17RA 2/2 mice injected with RRV were monitored for 3 weeks, and survival between the groups was compared applying the log-rank (Mantel-Cox) test (n pups/ group >22; *P < 0.05). Bar graphs are means 6 standard error of the mean, and unpaired t test was applied to test for significance with *P < 0.05, **P < 0.01, and ****P < 0.0001. Abbreviations: FC, Fold change; TC, T cells; BC, B cells.
were localized in the portal triad in close proximity to the interlobular bile ducts, as detected by IHC against CD11c (Fig. 6F) . 7A) . Automated image analysis revealed that the number of periportal IL-17A
PREVALENCE OF IL
1 cells was higher in subjects with BA compared to noncholestatic controls. Using CD68 IHC on liver sections, subjects with BA at diagnosis were qualitatively divided into two groups: those with absent or low number of CD68
1 cells and those with high prevalence of periportal CD68
1 MU (Fig. 7B) . Notably, the frequency of periportal IL-17A 1 cells was significantly higher in the second group. In this small cohort, demographics, short-term, and long-term outcomes were similar between the two groups (Supporting Table S1 ). 
HEPATIC Th17 RESPONSES PERSIST IN SUBJECTS WITH BA AND RAPIDLY PROGRESSIVE DISEASE
IL-17A
1 cells were highly prevalent in the portal triads in subjects with BA and progressive disease requiring LTx at less than 2 years of age, whereas in conditions like Alagille syndrome hepatic IL-17A 1 cells were inconspicuous at the time of LTx (Fig. 7C) . MNCs from fresh tissue of explanted livers were stimulated with phorbol 12-myristate 13-acetate and ionomycin and subjected to intracellular cytokine staining, which identified CD4 1 and CD8 1 lymphocytes as the predominant producers of IL-17A and IFN-c, respectively (Fig. 7D) . Circulating CD4 1 T cells in these patients displayed an activated phenotype with absent expression of CD127 compared to age-matched healthy controls (Fig. 7E) . These data suggest that IL-17A lymphocyte infiltration is associated with recruitment of CD68 1 iMU to the site of injury in human BA and that Th17 polarization of hepatic CD4 1 lymphocytes persists in patients with progressive disease requiring LTx.
Discussion
Our studies in experimental BA show that following postnatal RRV infection DCs are critical in polarizing Th17 lymphocytes orchestrating the postobstructive phase of intrahepatic bile duct injury. IL-17A is capable of inducing production of the chemokine ligand CCL2 by neonatal cholangiocytes, which then attracts CCR2 1
Ly6C
1 iMU to the site of epithelial injury (Fig. 8) .
Elevated plasma concentrations of IL-17A and infiltration of the liver with IL-17A
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2 MNCs (n 5 4 patients). (F) Representative photomicrographs of IHC against CD11c on sections from the liver of a patient with BA at diagnosis and from lymph node as positive control. Arrow denotes an interlobular bile duct. Bar 5 50 lm. Bar graphs are means 6 standard error of the mean. *P < 0.05, ***P < 0.001, and ****P < 0.0001, determined by paired t tests. Abbreviations: FSC, forward scatter; SSC, side scatter. during the late phase of BA. These findings are consistent with a recent report showing up-regulation of Th17-associated genes in hepatic leukocytes from RRVinfected neonatal mice. (17) However, based on ex vivo stimulation of purified hepatic leukocytes, this study concluded that cd T cells represented the primary cellular source for IL-17A production in experimental BA. In contrast, our studies using IL-17A-GFP reporter mice identify TCRab 1 lymphocytes, and not cd T cells, as the predominant cell type driving hepatic IL-17A responses during the postobstructive phase of murine BA. Our findings indicate a critical role for Th17 cells in orchestrating hepatobiliary injury in BA, which share similarities with the impact of Th17 cells on progression of inflammatory BEC injury in primary biliary cirrhosis and primary sclerosing cholangitis and in their murine models. (12, 18) Based on our studies and literature evidence, we propose a model for the pathogenesis of experimental BA, in which IL-17A 1 -producing cd T cells contribute to an early acute inflammatory response to RRV infection, whereas Th17 adaptive immune responses perpetuate intrahepatic BEC injury in the postobstructive phase of the disease.
We show that hepatic IL-17A responses depend on DCs in experimental BA. In vitro, coculture of RRVprimed DCs and CD4 lymphocytes amplifies production of IL-17A and IL-6. In vivo, DC depletion reduces Th17 polarization and is associated with reduced cholestasis. We show that innate NK and cd T lymphocytes infiltrate the liver early in the disease course, which is potentially linked to pDCs that populate the liver during the first 5 days after viral challenge and provide cytokine support for activation and survival of NK cells. (19) Activated CD4 1 lymphocytes emerge in the liver during the postobstructive phase of BA, coinciding with expansion of mDCs. Consequently, disrupting the DC-dependent polarization of Th17 lymphocytes in DT-treated CD11c/GFP/DTR mice or their effector function in IL-17RA 2/2 animals does not prevent ductal obstruction but attenuates the late BA phenotype, as evidenced by prevention of bile duct paucity and prolongation of survival.
The effects of IL-17A on neonatal bile duct epithelium have not been studied to date. Coexpression of IL-17RA with the BEC marker CK19 was detected on intrahepatic cholangiocytes from neonatal mice. BECs are sensitive to cytolysis induced by proinflammatory cytokines and immune-mediated injury. (20, 21) In our hands, rIL-17A does not kill neonatal BECs in vitro, but it induces expression of chemokines, like Ccl2. In experimental BA, elevated plasma concentration of CCL2 at d12pRRV coincides with population of the liver with Ly6C hi iMU. Blockade of the CCL2/ CCR2 interaction attenuates infiltration of the liver with iMU, and loss of IL-17A signaling results in down-regulation of hepatic CCL2 expression, reduced recruitment of iMU, and improved survival. Ly6C hi iMU produce high concentrations of tumor necrosis factor-a and other proinflammatory cytokines and contribute to toxin-induced liver inflammation and fibrosis. (22) During acute cholestasis in the bile duct ligation model, tumor necrosis factor-a induces apoptosis and inhibits regeneration of BECs. (23) This leads to a paucity of interlobular bile ducts forming a lumen and to histopathological changes similar to those of the dystrophic bile duct profiles we observed in experimental BA. IL-17A not only exerts effects on BECs but also up-regulates expression of Il-6 and Il-23p19 in CD11b 1 leukocytes from RRV-infected mice, which may help to maintain Th17 responses in the liver. Studies in carbon tetrachloride-induced liver injury reported that IL-17A stimulates expression of proinflammatory cytokines in Kupffer cells and activates hepatic stellate cells, promoting hepatic fibrosis. (24) In validation studies on archived and fresh liver tissues from subjects with BA we show that liver infiltration with conventional CD11c 1 human leukocyte antigen (HLA)-DR
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HEPATOLOGY, January 2017 CD127 low CD4 1 and CD8 1 T lymphocytes in the liver at the time of diagnosis. The frequency of hepatic pDCs, which are critical for initiation of murine BA, (19) is low in infants at diagnosis, supporting the notion that infants with BA are diagnosed at the late stage of their disease. By performing short-term stimulation and intracellular cytokine staining on hepatic MNCs from explanted livers of patients with progressive disease, we ascribe IL-17A production to CD4 1 CD3 1 lymphocytes, while IFN-c is primarily generated by CD8 1 T lymphocytes. Concordant with the murine studies, AE1/AE3 1 cholangiocytes and CD68
1 MU express IL-17RA in BA patients at the time of diagnosis, and the latter persist until LTx, suggesting that both BECs and MU are cellular targets of IL-17A in neonates. CCL2 was shown to be expressed by BECs and scar margin hepatocytes in infants with BA, and linked to activation of stellate cells, propagating biliary fibrosis. (25) Of note, abundance of periductal IL-17A
1 cells is associated with periportal infiltration of CD68
1 iMU, and these portal IL-17A 1 cells persist in the liver of patients with progressive disease. An increased number of periductal IL-17A
1 cells was linked to worse surgical outcome of KPE in Europe, (26) and elevated plasma levels of IL-17A-associated cytokines were determined in an Asian cohort of infants with BA. (27) Whether infiltration of the liver with Th17 lymphocytes and CD68
1 iMU at the time of diagnosis is linked to progressive intrahepatic bile duct injury following KPE in North America will require further investigations.
Collectively, our studies in the murine model and on human tissue samples suggest that CD11c 1 DCdependent polarization of CD4 1 T cells into Th17 cells is a key immunologic event during the postobstructive phase of BA. It governs CCL2 production by BECs and recruitment of CCR2 1 iMU to the intrahepatic bile ducts. Disruption of DC-dependent Th17 polarization of CD4 1 lymphocytes, of IL-17A signaling, or of the CCR2/CCL2 pathway decreases hepatic recruitment of iMU, prevents progressive destruction of interlobular bile ducts, alleviates cholestasis, and prolongs survival in experimental BA. Therefore, we have identified DCs, Th17 cells, and the CCL2/CCR2 axis as potential targets for adjuvant therapy in patients with BA.
